USP24 and plasma cell myeloma: However, upregulation of USP24 in response to USP9X knockdown, promoting myeloma cell survival, demonstrated the need for dual USP9X/USP24 inhibitors, prompting the development of EOAI3402143 (aka G9) by improving the properties of WP1130 [265].